Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib and Ultra-low Dose Radiotherapy in Early OA-EMZL
NCT06503276Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by Shanghai Ninth People's Hospital. Started Nov 2023; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on NCT06503276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503276.